China’s Growth in Partnership Deals with Pipeline Drugs

21st December 2017 (Last Updated December 21st, 2017 13:57)

Partnership deals that involve drugs in pipeline stage have shown a gradual increase of 8% for the US over the last 5 years. The US still remains to dominate the market, however partnership deals with drugs in pipeline stage for China has also shown a significant increase of 5% from 2013 to 2017.

China’s Growth in Partnership Deals with Pipeline Drugs
Figure 1:   % Partnership Deals with Pipeline Drugs from 2013 to 2017. BRICS countries include Brazil, Russia, India, China, South Africa Source: GlobalData, Pharma Intelligence Center, Deals Database [Accessed Dec, 2017]

Partnership deals that involve drugs in pipeline stage have shown a gradual increase of 8% for the US over the last 5 years. The US still remains to dominate the market, however partnership deals with drugs in pipeline stage for China has also shown a significant increase of 5% from 2013 to 2017.

Figure 1 shows the % of Partnership Deals with Pipeline Drugs for the US compared to the BRICS* countries over the last 5 years. The BRICS* countries continue to own a third of the global share of these deals where China and Brazil combined have more than half of the BRICS countries partnership deals in addition to showing the most % increase over time.

China tend to prefer partnership strategic alliance deals as they can share resources at an affordable cost instead of the higher risks and increased regulations required with acquisitions.